Monopar Therapeutics Announces Positive Phase 2 Study Results for ALXN1840 in Wilson Disease
Key Highlights
- Monopar Therapeutics Inc. (Nasdaq: MNPR) announced the publication of results from its Phase 2 ALXN1840-WD-204 clinical study.
- The study demonstrated that ALXN1840 (tiomolibdate choline) significantly improves copper balance in patients with Wilson disease.
- The company believes these results reinforce ALXN1840’s promise as a meaningful new treatment option for Wilson disease.
- This development could be price sensitive and may impact the company’s share value due to the clinical advancement and potential for regulatory filings.
Detailed Article
WILMETTE, Ill., May 19, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with serious diseases, today announced the publication of positive results from its pivotal Phase 2 ALXN1840-WD-204 clinical study. These findings were shared in a press release and are seen as a significant milestone in the company’s research and development efforts.
The Phase 2 study demonstrated that ALXN1840 (tiomolibdate choline) substantially improves copper balance in patients with Wilson disease, a rare and potentially life-threatening genetic disorder characterized by the accumulation of copper in the body’s organs. The management of copper balance is critical for Wilson disease patients, and current treatment options are limited.
According to Monopar, these results support ALXN1840’s potential to rapidly and effectively restore copper balance, which could position it as a next-generation therapeutic for Wilson disease. The company believes this data will serve as an important foundation for ongoing and future regulatory filings and commercialization strategies.
Potential Impact for Shareholders
- Clinical milestone: The successful Phase 2 results validate ALXN1840’s mechanism of action and therapeutic potential, which is significant for both patients and investors.
- Regulatory path: Monopar intends to initiate regulatory processes for ALXN1840, which, if successful, could lead to eventual FDA approval and commercial launch.
- Market opportunity: Wilson disease represents a clear unmet medical need, and a new, effective treatment could capture significant market share. Positive study results may attract increased interest from investors and potential partners.
- Share price sensitivity: News of promising clinical trial results, especially in a rare disease with limited treatments, is typically price sensitive. Investors should be aware that the share value could react to these developments as the market digests the news and anticipates next steps.
Forward-Looking Statements
Monopar cautions that forward-looking statements in its communications involve risks and uncertainties, including but not limited to the regulatory approval process, market acceptance, competition, and the company’s ability to raise sufficient funds for continued development, regulatory milestones, and commercialization. Actual results may differ materially from those anticipated due to a variety of factors, including those described in the company’s filings with the Securities and Exchange Commission.
Contact Information
- Investor Relations Contact: Quan Vu, Chief Financial Officer
- Email: [email protected]
- Follow Monopar on social media: X (Twitter): @MonoparTx | LinkedIn: Monopar Therapeutics
Disclaimer: This news article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with their financial advisors before making any investment decisions. All statements, except for statements of historical fact, are forward-looking and involve risks and uncertainties. Monopar does not undertake any obligation to update forward-looking statements as a result of new information, future events, or otherwise.
